NCT00625586View on ClinicalTrials.gov

Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 15, 2008

Primary Completion Date

January 21, 2009

Study Completion Date

March 18, 2009

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

RAV12

RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.

DRUG

Gemcitabine

1000 mg/m2 weekly, intravenously

Trial Locations (2)

94080

MacroGenics, Incorporated, South San Francisco

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
lead

MacroGenics

INDUSTRY